Parâmetros clínicos e laboratoriais na intoxicação aguda pela dapsona by Carrazza, Maria Zilda N et al.
Journal of Public Health
Universidade de São Paulo
Faculdade de Saúde Pública
VOLUME 34
NÚMERO 4
AGOSTO 2000
Revista de Saúde Pública
p. 396-401
CARRAZZA a Maria Zilda N, Francisco R Carrazzab and Seizi Ogac  Clinical and laboratory parameters in dapsone
acute intoxication  Rev. Saúde Pública, 34 (4): 396-401 , 2000 www.fsp.usp.br/rsp
Clinical and laboratory parameters in dapsone
acute intoxication
Parâmetros clínicos e laboratoriais na
intoxicação aguda pela dapsona
Maria Zilda N Carrazzaa, Francisco R Carrazzab and Seizi Ogac
aPrograma de Controle de Intoxicações, Secretaria de Saúde do Município de São Paulo. São Paulo, SP,
Brasil. bDepartamento de Pediatria da Faculdade de Medicina da Universidade de São Paulo. São
Paulo, SP, Brasil. cDepartamento de Análises Clínicas e Toxicologia da Faculdade de Ciências Farmacêu-
ticas da Universidade de São Paulo. São Paulo, SP, Brasil
396 Rev Saœde Pœblica 2000;34(4):396-401
www.fsp.usp.br/rsp
Abstract
Objective
To determine the severity of dapsone (DDS) acute intoxication – an uncommon
medical event – using clinical and laboratory parameters.
Methods
Two hundred and seventy four patients with acute DDS intoxication, aged 1 month
to 50 years old, were studied and classified into four age groups. Clinical evaluation
was assessed through a protocol and correlated with laboratory parameters.
Spectrophotometric methods were used to analyze methemoglobinemia (MHbp)
and dapsonemia (DDSp).
Results
The most prevalent clinical sign of intoxication was cyanosis, seen in 65.7% of the
patients and in 100% of children less than 5 years of age. According to laboratory
criteria, MHbp-related severe clinical intoxication was seen in 56.2% and DDSp-
related occurred in 58% of the patients. Regarding DDSp, intoxication was considered
severe when 20 tablets (100 mg each) were ingested, a median of 29 µg/ml. Regarding
MHbp, intoxication was severe when 7.5 tablets were ingested, a median of 38% of
the total Hb. The correlation between MHbp and DDSp was statistically significant
(n=144, r=0.32, p<0.05). Negative correlation was observed between MHbp and
the time elapsed since DDS intake (n=124, r=-0.34, p<0.001). There was also a
negative correlation between DDSp and the time elapsed since DDS intake (n=63,
r=-0.35, p<0.0001).
Conclusions
Longitudinal analysis showed a significant association between methemoglobinemia
and the time elapsed after the intake (t), according to the equation:
Dapsonemia = 12.9256 - 0.0682t + 0.234 methemoglobinemia
Resumo
Objetivo
Definir a gravidade da intoxicação aguda por dapsona (DDS) – uma ocorrência
médica não usual – usando parâmetros clínicos e laboratoriais.
Métodos
Foram estudados 274 pacientes intoxicados por DDS, divididos em quatro grupos
etários; as idades variaram de um mês a 50 anos. A avaliação clínica foi efetuada
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por meio de um questionário e correlacionada com parâmetros laboratoriais. A
metemoglobinemia (MHbp) e a dapsonemia (DDSp) foram analisadas por métodos
espectrofotométricos.
Resultados
O sinal clínico mais prevalente da intoxicação foi a cianose, presente em 65,7%
dos pacientes e em 100% das crianças menores de 5 anos. A intoxicação grave,
definida laboratorialmente, de acordo com a MHb ocorreu em 56,2% dos pacientes
e, de acordo com a DDSp, em 58%. A intoxicação foi grave, de acordo com a
DDSp, quando houve a ingestão mediana de 20 comprimidos (100mg cada) e, de
acordo com a MHbp, quando a ingestão foi de 7,5 comprimidos. A mediana de
MHbp foi de 38% da Hb total. A correlação entre MHbp e a DDSp foi significativa
(n=144, r=0,32, p<0,05). Observou-se uma correlação negativa entre a MHbp e
o tempo decorrido da intoxicação (n=124, r=-0,34, p<0,001). Correlação negativa,
entre o DDSp e o tempo decorrido da intoxicação, também foi observada ( n=63,
r=-0,35, p<0,0001).
Conclusões
A gravidade da intoxicação representada pelos valores da dapsonemia, determinada
pela análise longitudinal, demonstrou uma associação significativa entre
metemoglobinemia e o tempo decorrido da ingestão (t), de acordo com a equação:
Dapsonemia = 12,9256-0,0682.t + 0,234.metemoglobinemia
INTRODUCTION
Dapsone – DDS – (4,4’-diaminodiphenyl
sulphone) is a drug of the sulphone group with bac-
teriostatic and low bactericide activities, used as
an important component of the multidrug treatment
of leprosy.16 This drug may produce adverse effects
such as methemoglobinemia, hemolytic anemia, and
less often agranulocytosis, peripheral neurophathy,
psychoses, hepatotoxicity and renal toxicity.14
These adverse effects may be related to dose or
individual susceptibility. Apart from adverse and
toxic effects, DDS hypersensitivity is associated
with multidrug therapy.11
Brazil is ranked second in the number of leprosy
cases. DDS as a monotherapy or part of a multidrug
therapy has been used to treat leprosy and other dis-
eases, exposing a great number of individuals to acute
intoxication.
The patients included in this study were those
who were taking DDS as part of the leprosy treat-
ment, and other people socially related to them, in-
cluding children.
Based on clinical and laboratory data and the avail-
able literature, degrees of intoxication severity were
hypothesized, according to MHbp and DDSp8,9 mea-
sures.8,9 MHbp values of less than 16% indicate
mild intoxication, 16% to 30% moderate, and 30% or
more severe. DDSp values up to 10 times the thera-
peutic level (1 µg/ml) were considered mild, 10 to
21(10-21 µg/ml) were moderate and over 21 times,
severe.
The objective of the study was to provide clinical
and laboratory data to determine the severity of DDS
acute intoxication.
METHODS
A retrospective evaluation was made in the records
of 274 patients intoxicated with DDS. The patients
age ranged from 1 month old to 50 years old and, for
physiological reasons, they were classified into 4 age
groups: Group 1 (under age 5), group 2 (ages 5 to 12),
Group 3 (ages 13 to 18), and Group 4 (ages 19 to 50).
Blood samples were analyzed at the S. Paulo Poison
Control Center (PCC-SP) Laboratory between Janu-
ary 1985 and December 1995. Samples came from dif-
ferent hospitals of the greater S. Paulo area, since the
PCC-SP Laboratory was the only one in the city well
equipped to perform emergency toxicological analy-
ses. A clinical history was obtained from each patient
and a protocol was then filled out by a member of the
laboratory staff and checked by one of the research-
ers (MZNC). The samples were immediately processed
according to the laboratory routine for toxicological
analyses. During the patients’ treatment, other blood
samples were drawn and more information collected.
The number of samples received per patients varied
from 1 to 10, and in some severe cases the follow-up
was of more than 10 days.
The following toxicological analyses were per-
formed: methemoglobinemia (814 determinations in 274
patients) and dapsonemia (171 determinations in 63
patients). Methemoglobinemia was determined using
the modified Evelyn & Malloy method (unpublished).7
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To determine the dapsonemia, Tawada & Midio
method (1989) was used.15 The analyses were per-
formed in a Beckman DB-GT spectrophotometer.
Statistical analysis
The Center for Disease Control (Atlanta,
Georgia,USA) Epi Info Version 6.04 was processed as
a database for epidemiological statistical analysis in
PCs. Nonparametric statistical analyses, including
correlations, were carried out.
The method for analyzing each risk factor contri-
bution (such as independent variables) on the in-
toxication severity (seen as dependent variable) was
the “generalized linear models for dependent data,
via generalized estimating equations” (GEE Version
4.4, 1996 from program S-PLUS, 1988, 1994, by Math
Soft Inc.).1,6
The significance level was 5%.
RESULTS
Table 1 shows the 266 patients with dapsone intoxi-
cation (age or gender information was missing in eight
patients) distributed by age and gender: 162 were fe-
males (61%) and group 1(< 5 years old) was the larg-
est one (55.2%). The most common clinical symptoms
were cyanosis, vomiting, mental confusion, tachycar-
dia and dyspnea. There was a relationship between
the number of tablets ingested (confirmed by the pa-
tient or person in charge) and the symptoms seen in
120 intoxicated patients. Cyanosis was present in more
than 90% of all patients, and tachycardia in about 30%.
Vomiting and dyspnea occurred in 15%. Mental con-
fusion was seen in 13.7% and when 10 DDS tablets
(100 mg) or more were ingested.
Circumstantial causes are those presumably respon-
sible for the acute intoxication.
Table 2 shows the number of patients and percent-
ages for each circumstantial causes, their respective
MHbp and DDSp medians and ranges.
Table 3 exhibits the means, medians and ranges of
MHbp in the 265 patients studied and distributed into
four age groups. The MHbp values were similar in all
age groups.
Causes Patients MHbp%* Patients DDSp µg/mL
N(%) Median (range) N(%) Median (range)
Suicide attempts 70 (25.6) 36.5 (3.5-94.0) 32 (54.2) 22.4 (5.5-65.0)
Accident 148 (54.2) 31.3 (3.2-78.0) 14 (23.7) 10.0 (0.8-39.2)
Unknown causes 30 (11.0) 28.5 (4.1-43.1) 4 (6.8) 12.6 (6.9-39.2)
Improper intake 14 (4.8) 21.0 (8.7-34.2) 6 (10.1) 9.2 (1.6-29.6)
Other causes 12 (4.4) 30.3 (12.0-53.0) 3 (5.1) 10.2 (9.5-10.6)
Table 2 – Prevalence of circumstantial causes of intoxication, medians and ranges of methemoglobinemias and dapsonemias.
*Percentual of methemoglobin in relation to total Hb.
Table 4 shows the means, medians and ranges of
DDS plasma concentration in the four groups. The
DDSp was significantly lower in group 2 (p<0.05).
Using the methemoglobinemia as severity criteria,
9.5% of the patients developed mild, 33.9% moderate
and 56.4% severe intoxication. According to
dapsonemia levels, 35.6% patients showed mild, 25.4%
moderate and 39% severe intoxication.
1 < 5 147 (55.2) 66 81
2 5 - 12 33 (12.4) 12 21
3 13 - 18 39 (14.7)   7 32
4 19 - 50 47 (17.7) 19 28
Table 1 – Groups of patients distributed by age and sex.
Groups Age (years) Patients Male Female
N (%)
G1 147 31.6 ± 0.88 5.1-58.0 31.2
G2 33 31.6 ± 2.54 8.6-78.0 31.2
G3 38 32.5 ± 2.92 3.5-94.0 33.8
G4 47 34.5 ± 2.29 3.2-90.0 34.5
Table 3 – Methemoglobinemia in  all  groups of intoxicated
patients.
SE = standard error
* percentual of methemoglobinemia in relation to total Hb
Group N Methemoglobinemia (%)*
Mean ± SE Range Median
1 15 15,7 ± 2,96 5.5-39.2 10.2
2 7 7.6 ± 2,35 0.8-18.1         5.5*
3 23 23.3 ± 3.67 2.5-65.0 18.0
4 13 24.5 ± 4,77 2.1-57.8 24.0
Table 4 – Dapsonemia in all groups of intoxicated patients.
* (p<0.05) in relation to the  groups 3 and 4 ( Kruskal-Wallis)
Group N Dapsonemia (µg /mL)
Mean ± SE Range Median
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Table 5 shows that 88.4% of the patients who had
taken between 4 and 7.5 tablets (100 mg each) had
moderate to severe intoxication when evaluated with
MHbp criteria. Moderate and severe intoxication oc-
curred in 32.2% and 56.2% of the cases, respectively.
The median MHbp was 38% of the total Hb. Accord-
ing to DDSp levels determined in 31 patients who con-
firmed taking the drug, 58% had severe intoxication.
With a median dapsone intake of 20 tablets, DDSp
median was 29 µg/ml.
MHbp and DDSp showed a significant correlation
(n=144, r=0.32, p<0.05). Methemoglobinemia and time
elapsed after the intake revealed a significant nega-
tive correlation (n=124, r = -0.34, p<0,001).
DDSp and the number of hours elapsed after the
intake showed a significant negative correlation (n=63,
r = -0.35, p<0.0001).
The longitudinal analysis followed a GEE model.
Dapsonemia values were considered the dependent
variable. Independent variables were: the number
of tablets ingested, methemoglobinemia levels, time
elapsed after intake, MHbp levels, age and gender.
Initially, the model used was represented by the fol-
lowing general expression:
Dapsonemia = number of tablets + time elapsed after
intake + methemoglobinemia + age + gender.
Wald’s test was applied to evaluate the model vari-
ables. The association between the 5 independent
variables and the intoxication severity was only sta-
tistically significant for the time elapsed and meth-
emoglobinemia. Therefore:
Dapsonemia = time elapsed after intake + methemo-
globinemia
In the above expression, there is a significant asso-
ciation between the intoxication severity (represented
by dapsonemia values), methemoglobinemia, and the
time elapsed after intake (t). Replacing the calculated
factors, dapsone plasma concentration can be esti-
mated by the following equation:
Dapsonemia = 12.9256 – 0.0682t + 0.234 methemo-
globinemia
DISCUSSION
The Poison Control Center Laboratory analyzed
clinical and laboratory data of patients with acute
dapsone intoxication between January 1985 to De-
cember 1995. The average number of patients was
32±4 per year for the first 6 years, and 19±1 (p<0.05)
for the second period (1990 to 1995). The decrease in
the number of DDS intoxication cases over the last
five years could be attributed to a better control of
the distribution of DDS tablets (given to the patients)
and change in the tablets package. DDS intoxication
in developed countries is almost exclusively related
to suicide attempts and are always medical anec-
dotes.10 Dapsone acute intoxication in developed
countries usually occurs in patients using DDS for
several conditions such as dermatitis herpetiformis,
malaria prophylaxis, polychondritis, rheumathoid
arthitis, Pneumocystis carinii pneumonia in AIDS
patients and others, while in Brazil and India its main
use is in the treatment of leprosy.
The symptoms in all 4 age groups were cyanosis, vom-
iting, tachycardia and dyspnea. In Group 1, all patients
(100%) had cyanosis, probably due to the immaturity of
their defense mechanisms against the chemical aggres-
sor. Two patients had convulsions. One of them, aged
17, had taken 100 mg of DDS daily, and his methemoglo-
binemia was 18%. The other, a boy aged 9, had an initial
methemoglobinemia level of  33%. Visual hallucinations
*percentual of methemoglobinemia in relation to total Hb
Mild (<16%) 14 (11.6) 4 9.4
Moderate (16<30%) 39 (32.2) 4 23.9
Severe (≥30%) 68(56.2) 7.5 38.0
Dapsonemia (µg/ml)
Mild (<10 µg/ml) 8 (25.8) 6.5 6.7
Moderate (10<21 µg/ml) 5 (16.2) 3 11.5
Severe (≥21 µg/ml) 18 (58.0) 20 29.0
Table 5 – Severity of intoxication, median of intake of DDS tablets (100 mg each) and respective methemoglobinemia
and dapsonemia medians.
Severity N (%) Median of Methemoglobinemia*
ingested tablets (%)
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were present in 3 patients, two of who were children
under age 5 and the third was a teenager.
When intake was between 1 and 5 DDS tablets, 100%
of patients in Group 1 presented cyanosis and 29.3%
tachycardia.
Schvartsman & Marcondes13 reported 12 intoxi-
cated children who presented cyanosis, 75% nausea
and vomiting, 33.3% dyspnea and 66.6%, neurologi-
cal manifestations. Cyanosis was the major sign men-
tioned in all studies on dapsone intoxication since
the first case reported by Davies3 (1950) until those
observed by Hansen3,4 (1994). Methemoglobin pro-
duction in dapsone intoxicated patients is related to
the formation of hidroxylamine metabolites. Colleman
& Jacobus2 used a combination with an initial dap-
sone hydroxylamine/hemoglobin ratio of 1:16 and
there was seen more than 30% oxidation of the he-
moglobin after five minutes of incubation at 37°C,
showing that one hydroxylamine molecule can react
with more than five molecules of hemoglobin.
Circumstantial causes of DDS intoxication showed
that suicide attempts (94%) predominated in the
groups of adolescents and adults (Groups 3 and 4)
and 71% of them were females. Group 1 had the lowest
intake with 68% of children having ingested 1 to 4
tablets, with a median of 4, whereas the adolescent
group (Group 3) showed a median of 10 tablets, and
the median for adults (Group 4) was 20 tablets.
DDS intoxication was severe in 58% of the cases,
with an intake of 20 tablets when tested for DDSp and
7.5 tablets when MHbp was evaluated.
In this study, 154 patients had an initial MHbp of
more than 30%, and 65 presented more than 40%. There
is no indication in the medical literature of such high
methemoglobinemia levels in cases of DDS intoxica-
tion, as was seen in these patients.
Methemoglobinemia has been the most important pa-
rameter monitored in acute DDS intoxication. For that
reason, an oximeter to measure the MHbp should not be
used after the beginning of the therapy with methylene
blue (1mg/kg), since errors in the instruments readings
may occur regarding the absorption of light at the same
wavelength of methemoglobin and methylene blue.5,8,12
The means and medians of the dapsone plasma
concentration were similar in all groups, except in
Group 2, where it was significantly lower. This group
consisted of children aged 5 to 12 who ingested a
smaller amount of tablets and whose main cause of
intoxication was accidental. Higher methemoglobin-
emia values and DDS plasma concentrations were
seen in adults, where the predominant cause of in-
toxication was suicide attempts.
Severity when evaluated with DDS plasma levels
indicated that patients under age 13 presented mild to
moderate intoxication, while adolescents and adults
showed severe intoxication in 50% of the cases.
When intoxication severity was evaluated by mea-
suring MHbp and its distribution in the 4 groups,
moderate and severe intoxication occurred in Group 1
(57%). DDS median intake in this group was 4 tablets.
In the groups of adolescents and adults, intoxication
severity was generally higher (median = 10 and 20,
respectively) due to the fact that dapsone intake was
also higher.
Initial DDSp and MHbp levels showed a signifi-
cant correlation. There was no correlation between
the time elapsed after intake and the initial measure-
ments of MHbp or DDSp. However, when time
elapsed was correlated with all methemoglobin or
DDS measurements, there was seen a significant
negative correlation.
Longitudinal analysis (GEE) of intoxication severity
revealed a significant correlation only between meth-
emoglobinemia and time elapsed after the intoxication
onset. This suggests that the dose is not the most
important factor in determining the DDS intoxication
severity. The mathematical model allows a good esti-
mate of DDS plasma levels, since the methemoglobin-
emia values and the time elapsed after dapsone intake
are known.
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